AR048617A1 - Antagonistas del receptor a2a de la adenosina con estructura de pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina. - Google Patents

Antagonistas del receptor a2a de la adenosina con estructura de pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina.

Info

Publication number
AR048617A1
AR048617A1 ARP050101559A ARP050101559A AR048617A1 AR 048617 A1 AR048617 A1 AR 048617A1 AR P050101559 A ARP050101559 A AR P050101559A AR P050101559 A ARP050101559 A AR P050101559A AR 048617 A1 AR048617 A1 AR 048617A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
hydroxyalkyl
group
alkoxyalkyl
Prior art date
Application number
ARP050101559A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR048617A1 publication Critical patent/AR048617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a antagonistas del receptor A2A de la adenosina con estructura de pirazolo-[4,3-E]-1,2,4-triazolo-[1,5-C]-pirimidina, y composiciones farmacéuticas que los contienen y usos. Reivindicacion 1: Un compuesto que tiene la formula estructural (1) o una sal aceptable para uso farmacéutico del mismo, donde R es R6-fenilo, R6-furanilo, R6-tienilo, R6-piridilo, R6-piridilo N-oxido, R6-oxazolilo, R6-pirrolilo o cicloalquenilo; R1, R2, R3, R4 y R5 se seleccionan independientemente del grupo integrado por H, alquilo y alcoxialquilo; R6 es 1 a 3 sustituyentes independientemente seleccionados del grupo integrado por H, alquilo, -CF3, halogeno, -NO2, -CN, -NR7R8, alcoxi, alquiltio, alquilsulfinilo y alquilsulfonilo; R7 es H o alquilo; R8 es H, alquilo, alquilC(O)- o alquil-SO2-; Z es R9, R10-arilo o R9,R10-heteroarilo; R9 es alquenilo, hidroxialquilo, alcoxialquilo, alcoxi-alcoxi-alquilo-, (di-alcoxi)-alquilo, (hidroxi)-alcoxialquilo, R15-cicloalquilo, R15- cicloalquilalquilo, cicloalquil-oxi, cicloalquil-O-alcoxi, cianoalquilo, -C(O)R13, -N(R11)(R12), N(R11)(R12)-alquilo-, -C(O)N(R13)(R16), -alquilen-C(O)-N(R11)2, -C(O)-(R15-heterocicloalquilo), R15-heterocicloalquil-alquilo, R15-heterocicloalquil- alcoxi, R19-heteroarilo, CF3-alquilen-O-alquilo, CF3-hidroxialquilo, (CF3)(hidroxi)alcoxi, ciano-alcoxi, -alquilen-C(O)-O-alquilo, -SO2-N(alquilo)2, (cicloalquil)hidroxialquilo, (hidroxialquil)alcoxi, (dihidroxi)alquilo, (dihidroxi)alcoxi o - C(=NOR17)-CF3; R10 es 1 a 3 sustituyentes independientemente seleccionados del grupo integrado por H, alquilo, alquenilo, hidroxi, alcoxi, hidroxialquilo, hidroxialcoxi, alcoxialquilo, alcoxialcoxi, alcoxi-alcoxi-alquilo-, (di-alcoxi)-alquilo, (hidroxi)-alcoxialquilo, R15-cicloalquilo, R15-cicloalquilalquilo, cicloalquil-oxi, cicloalquil-O-alcoxi, alquil-SO2-, alquil-SO-, halo, -CN, cianoalquilo, -CHF2, -CF3, -OCHF2, -OCF3, -C(O)R13, -O-alquilen-C(O)OR13, -C(O)O-alquilo, -N(R11)(R12), N(R11)(R12)-alquilo, N(R11)(R12)-alcoxi, -C(O)N(R13)(R16), R19-heteroarilo, R15-heterocicloalquilo, R15-heterocicloalquil-alquilo, R15-heterocicloalquil-alcoxi, R15-heterocicloalquil-oxi, CF3-alquilen-O-alquilo, CF3-hidroxialquilo, (CF3)(hidroxi)alcoxi, ciano-alcoxi, -alquilen-C(O)-O-alquilo, -SO2-N(alquilo)2, (cicloalquil)hidroxialquilo, (hidroxialquil)alcoxi, (dihidroxi)alquilo, (dihidroxi)alcoxi, -C(=NOR17)-alquilo y -C(=NOR17)-CF3; o un grupo R9 y un grupo R10 en átomos de anillos de C adyacentes juntos forman -O-(CH2)2-O-, -CH2-O-(CH2)2-O-, -O-(CH2)2-, -(CH2)3-O-, -O-(CH2)3-O-, -(CH2)3- o -CH2-CH=CH-, done el anillo formado por los sustituyentes R9 y R10 y los átomos de C del anillo al cual están unidos están sustituidos con R16; o un grupo R9 y un grupo R10 en átomos de anillos de C adyacentes juntos forman -N(R11)-C(O)-O-, -N(R11)-C(O)-S- o -N(R12)-(CH2)2-; o un grupo R9 y un grupo R10 en átomos de anillos de C adyacentes juntos forman -(CH2)2CH(OR18)- , -CH2CH(OR18)CH2-, -(CH2)3CH(OR18)-, -(CH2)2CH(OR18)CH2-, -(CH2)2C(O)-, -CH2C(O)CH2-, -(CH2)3C(O)-, -(CH2)2C(O)CH2-, -O(CH2)2CH(OR18)- o -OCH2CH(OR18)CH2-, donde el anillo formado por los sustituyentes R9 y R10 y los átomos de C del anillo al cual están unidos está sustituido opcionalmente en un átomo de C con hidroxialquilo o alcoxialquilo; cada R11 se selecciona independientemente del grupo integrado por H y alquilo; cada R12 se selecciona independientemente del grupo integrado por H, alquilo, cicloalquilo, hidroxialquilo, alcoxialquilo, -C(O)-alquilo, -C(O)O-alquilo, (alcoxi)hidroxialquilo, alcoxialquil-C(O)-, -SO2alquilo, -alquilen-C(O)alquilo y -alquilen-C(O)O-alquilo; R13 es H, alquilo o -CF3, R15 es 1 a 3 sustituyentes independientemente seleccionados del grupo integrado por H, alquilo, -OH, alcoxi, alcoxialquilo e hidroxialquilo, o dos sustituyentes R15, tomados junto con el C al cual están unidos, forman un grupo -C(=O)-, R16 es H, alquilo, alcoxialquilo, OH o hidroxialquilo; R17 es H o alquilo; R18 es H o alquilo, y R19 es 1 o 2 sustituyentes independientemente seleccionados del grupo integrado por H, alquilo, hidroxialquilo, alcoxialquilo, -C(O)N(R11)(R12) y -N(R11)2.
ARP050101559A 2004-04-21 2005-04-20 Antagonistas del receptor a2a de la adenosina con estructura de pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina. AR048617A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56391304P 2004-04-21 2004-04-21
US60996604P 2004-09-15 2004-09-15

Publications (1)

Publication Number Publication Date
AR048617A1 true AR048617A1 (es) 2006-05-10

Family

ID=34966464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101559A AR048617A1 (es) 2004-04-21 2005-04-20 Antagonistas del receptor a2a de la adenosina con estructura de pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina.

Country Status (17)

Country Link
US (1) US7709492B2 (es)
EP (1) EP1745047B1 (es)
JP (2) JP2007533754A (es)
KR (1) KR20060135901A (es)
AR (1) AR048617A1 (es)
AT (1) ATE461932T1 (es)
AU (1) AU2005236059B2 (es)
CA (1) CA2563635A1 (es)
DE (1) DE602005020127D1 (es)
ES (1) ES2342082T3 (es)
HK (1) HK1095818A1 (es)
IL (1) IL178674A0 (es)
MX (1) MXPA06012231A (es)
NZ (1) NZ550591A (es)
PE (1) PE20060185A1 (es)
TW (1) TW200538118A (es)
WO (1) WO2005103055A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522326A (en) * 2000-05-26 2006-03-31 Schering Corp Adenosine A2A receptor antagonists
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
ES2328581T3 (es) 2003-09-19 2009-11-16 Janssen Pharmaceutica Nv Acidos 4-((fhenoxialquil)tio)-fenoxiaceticos y analogos.
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
CN101084205A (zh) * 2004-12-13 2007-12-05 艾尼纳制药公司 作为5ht2c受体调节剂以治疗与其相关病症的n－联芳基和n－芳基杂芳基哌嗪衍生物
CA2594987A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Therapeutic agent for constipation
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP2009508871A (ja) * 2005-09-19 2009-03-05 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとしての２−ヘテロアリール−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジン
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
WO2009111449A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
WO2010068756A2 (en) * 2008-12-10 2010-06-17 Thesis Chemistry, Llc Process for manufacture of optically active 2-(acyloxymethyl)-1, 3 oxathiolanes
TW201036614A (en) * 2008-12-30 2010-10-16 Arqule Inc Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US8431699B2 (en) * 2009-02-27 2013-04-30 Vertichem Corporation Method for manufacture of 2-oxoimidazolidines
ES2487616T3 (es) 2009-03-10 2014-08-22 Takeda Pharmaceutical Company Limited Derivados de benzofurano
TW201100427A (en) * 2009-03-31 2011-01-01 Arqule Inc Substituted heterocyclic compounds
TWI508960B (zh) * 2009-10-08 2015-11-21 Sanofi Aventis 作為ｐｇｄｓ抑制劑之苯基二唑衍生物
US9006177B2 (en) * 2010-09-24 2015-04-14 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2797880B1 (en) * 2011-12-27 2017-03-01 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating epilepsy
HUE059990T2 (hu) * 2017-03-30 2023-01-28 iTeos Belgium SA 2-Oxo-tiazol-származékok A2A inhibitorként és a rákos megbetegedések kezelésében alkalmazható vegyületekként
TWI801372B (zh) * 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
CN108218796A (zh) * 2017-12-31 2018-06-29 佛山市赛维斯医药科技有限公司 含酰肼结构的化合物、制备方法及其用途
CN108191775A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一种末端烯丙基丙酰肼结构化合物及其用途
CN108148004A (zh) * 2017-12-31 2018-06-12 佛山市赛维斯医药科技有限公司 一种含丙酰肼和嘧啶结构的化合物、制备方法及其用途
CN107935953A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 含末端烯键和酰肼结构的comt抑制剂、制备方法及其用途
MX2020010618A (es) 2018-04-08 2020-11-12 Beigene Ltd Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
BE1026615B1 (fr) * 2018-09-27 2020-07-06 Iteos Therapeutics S A Combinaison d’un inhibiteur du récepteur a2a et d'un agent anticancéreux
EP4410375A2 (en) * 2018-09-11 2024-08-07 iTeos Belgium SA Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
BE1026758B1 (fr) * 2018-09-11 2020-06-09 Iteos Therapeutics S A Composition pharmaceutique comprenant des dérivés de thiocarbamate inhibiteurs d’a2a
US11427594B2 (en) 2018-09-27 2022-08-30 iTeos Belgium SA Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers
BE1026602B1 (fr) * 2018-09-27 2020-06-18 Iteos Therapeutics S A Inhibiteurs d’a2a ne penetrant pas dans le cerveau et methodes d’utilisation dans le traitement de cancers
CR20210271A (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
US20220235056A1 (en) * 2019-05-03 2022-07-28 Nektar Therapeutics Adenosine 2 receptor antagonists
US20230024108A1 (en) * 2019-07-17 2023-01-26 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
DE69428977T2 (de) 1993-07-27 2002-07-11 Kyowa Hakko Kogyo Co., Ltd. Arzneimittel gegen Parkinsonsche Krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
NZ522326A (en) 2000-05-26 2006-03-31 Schering Corp Adenosine A2A receptor antagonists
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
DE60335294D1 (de) 2002-12-19 2011-01-20 Schering Corp Dlung des extrapyramidalen syndroms
DE602004021250D1 (de) * 2003-04-23 2009-07-09 Schering Corp 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4-triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten

Also Published As

Publication number Publication date
US7709492B2 (en) 2010-05-04
NZ550591A (en) 2010-10-29
WO2005103055A1 (en) 2005-11-03
EP1745047A1 (en) 2007-01-24
HK1095818A1 (en) 2007-05-18
TW200538118A (en) 2005-12-01
ES2342082T3 (es) 2010-07-01
ATE461932T1 (de) 2010-04-15
AU2005236059B2 (en) 2009-01-15
JP2008231111A (ja) 2008-10-02
CA2563635A1 (en) 2005-11-03
KR20060135901A (ko) 2006-12-29
IL178674A0 (en) 2007-02-11
EP1745047B1 (en) 2010-03-24
MXPA06012231A (es) 2006-12-15
PE20060185A1 (es) 2006-03-20
JP2007533754A (ja) 2007-11-22
US20050239795A1 (en) 2005-10-27
DE602005020127D1 (de) 2010-05-06
AU2005236059A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
AR048617A1 (es) Antagonistas del receptor a2a de la adenosina con estructura de pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina.
AR044041A1 (es) Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina
JP2019512505A5 (es)
AU2020412429A1 (en) Substituted tricyclic compounds
RU2013151803A (ru) Бициклические гетероциклические соединения и их применения в терапии
CN112771054A (zh) 作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
HRP20200556T1 (hr) Novi (hetero) aril-supstituirani-piperidinil derivati, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
AR045536A1 (es) Inhibidores de la fosfodiesterasa tipo -iv
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
HRP20140437T1 (hr) Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora
AR074814A1 (es) Pirimidinas sustituidas como antagonistas del receptor ccr2 y usos de las mismas en medicamentos.
JP2017533932A (ja) タンパク質キナーゼ阻害剤としての６−アミノ−７−ビシクロ−７−デアザ−プリン誘導体
AR062427A1 (es) Derivados heteroarilo como inhibidores de citocina
AR085406A1 (es) Oxazinopteridinas y oxazinopteridinonas n-sustituidas
PE20121276A1 (es) Compuestos espirociclicos que contienen nitrogeno y su uso medicinal
AR100530A1 (es) Compuestos antihelmínticos
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR061072A1 (es) Pirazolo [1,5- a ] pirimidinas
CN102159574A (zh) 三-环吡唑并吡啶激酶抑制剂
AR056206A1 (es) Pirazolpirimidinas como inhibidores de protein quinasas
AR070521A1 (es) Derivados de 4h-pirido[4,3-d]-pirimidin-4-ona,inhibidores de quinasas,composiciones farmaceuticas que los contienen,uso de los mismos para el tratamiento de enfermedades con proliferacion celular o autoinmunes y metodo de preparacion de intermediarios de sintesis .
AR072171A1 (es) Derivados de nicotinamida, composicion farmaceutica que los comprende y su uso en combinaciones y en la preparacion de un medicamento para el tratamiento del asma.
AR053436A1 (es) Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR062666A1 (es) Benzotriazoles como moduladores de quinasas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal